Kaposi's sarcoma-associated herpesvirus (KSHV) is a human -herpesvirus associated with the 21 development of Kaposi's sarcoma (KS). KSHV target cells include endothelial cells, B cells, 22 monocytes, epithelial cells, dendritic cells, macrophages, and fibroblasts. KSHV entry into target 23 cells is a complex multistep process and is initiated by the binding and interaction of viral envelope 24 glycoproteins with the cellular receptors. In our current studies, we have found that EphA4 promotes 25 KSHV gH/gL-mediated fusion and infection better than EphA2 in HEK293T cells indicating that 26
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5
EBV entry was only recently identified by us and another group (12, 13) . Both EBV and KSHV are 74 associated with epithelial cell cancers, indicating that the engagement of EphA receptors could be a 75 key commonality in the development of these malignancies. 76
In our current studies, we found that EphA4 functions as an entry receptor for KSHV. It is 77 intriguing that the two human -herpesviruses, EBV and KSHV, use EphA proteins as entry 78 receptors. Both EphA2 and EphA4 belong to the Eph receptor family, a large family of receptor 79 tyrosine kinases (RTKs). The Eph receptor family contains 14 members and is divided into two 80 classes, A and B, based upon sequence similarity and affinity with the 9 ephrin ligands (14). The 81
Eph receptors and their ligands have bi-directional signaling capacity, indicating that they can serve 82 as both receptors and ligands (14) . The Ephrin receptors transduce signals from the cell exterior to the 83 cell interior by ligand-induced activation of their kinase domain (15) . The function of the Eph family 84 includes boundary formation, cell migration, axon guidance, synapse formation, angiogenesis, 85 proliferation, and cell differentiation (15, 16) . Eph receptors have been implicated in regulating cell 86 migration, adhesion, proliferation, and differentiation (16). Altered expression patterns of Eph 87 receptors and ephrins (Eph receptor ligands) have been correlated with tumor behavior, such as 88 invasiveness, vascularization, metastatic potential, and patient prognosis (17). Overexpression of 89
EphA2 and EphA4 has been reported in gastric cancer, breast cancer, colon cancer, and prostate 90 cancer (17-24). In our current studies, we investigated and found that EphA4 functions as an entry 91 receptor of KSHV. Overall, our current findings broaden the knowledge of KSHV entry process 92 and herpesvirus entry in general and may facilitate the development of potential entry inhibitors 93 targeting KSHV infection. 94 6 EphA4 promotes both KSHV cell-cell fusion activity and infection. We recently discovered 97 that EBV uses EphA2 but not EphA4 as an epithelial cell entry receptor (12). EphA2 had previously 98 been shown to function as a KSHV entry receptor for endothelial and epithelial cells (10). In our 99 current studies, we investigated if EphA4 may also function in KSHV entry. Key in these studies 100 was the use of EBV gB in the KSHV fusion assay in place of KSHV gB. Our previous work had 101
shown that the KSHV cell-cell fusion assay was not as robust as the EBV fusion assay, making it 102 difficult to obtain reproducible and significant data (25, 26) . By replacing KSHV gB with EBV gB, 103 KSHV fusion is greatly enhanced with fusion levels much higher than that mediated by the EBV 104 glycoproteins (26). The exact nature of this enhancement is unknown, but likely is due to 105 differences in the fusion activity of EBV gB compared to KSHV gB although a role of gH/gL can not 106 be excluded. 107
To determine if EphA4 may trigger fusion, we transfected EBV gB with KSHV gH/gL and EBV 108 gH/gL as a control in CHO-K1 cells and quantified fusion with HEK293T target cells overexpressing 109 either EphA2 and EphA4. We found that overexpression of EphA4 induced higher fusion activity 110 for the EBV gB and KSHV gH/gL combination compared to when EphA2 was tested ( Fig. 1A) . 111
Our previous data showed that EphA2 but not EphA4 is required for EBV fusion activity (12) similar 112 to the results shown when EBV gB and EBV gH/L are used ( Fig 1A) . This published data combined 113 with the results shown in Fig. 1A suggest a specificity of EphA4 for KSHV gH/gL for fusion function 114 when compared to EBV gH/gL. To further examine if EphA4 is sufficient to induce fusion for 115 KSHV gH/gL, we examined fusion activity using a split GFP fusion assay and readily detected 116 fusion as monitored by the appearance of green cells indicative of fusion activity only when KSHV 117 gH/gL and EBV gB expressing cells were overlaid with cells that overexpress EphA2 or EphA4 (Fig.  118 1B). Similarly, EphA4 induced more fusion activity compared to EphA2, consistent with our 7 observation of greater fusion in HEK293T cells transfected with EphA4. To examine the effect of 120 EphA4 on KSHV infection of epithelial cells, we transfected HEK293T cells with control plasmid,  121 EphA2, EphA4, and EphA2/EphA4 and then infected the cells with KSHV virus expressing GFP. 122
Flow cytometry showed increased infection of KSHV in the presence of either EphA2 or EphA4 and 123 higher levels of fusion when both EphA2 and EphA4 were transfected. (Fig. 1C ). We also 124 examined infection by fluorescence microscopy (Fig. 1D ) which was consistent with the flow 125 cytometry data (Fig. 1C EphA2 and EphA4 as primary entry receptors in these cell types. To further confirm that EphA4 can 137 serve as a cellular receptor for KSHV infection, we generated EphA2 and EphA4 single and double 138 knockout cells using the CRISPR/Cas9 system in HEK293T cells. Following knockout, EphA2 cell 139 surface expression was determined by flow cytometry. As expected, there was a lack of EphA2 140 expression as analyzed by flow cytometry in the EphA2 single knockout cells and in the 141 8 We analyzed EphA4 expression by Western blotting since the available antibodies did not work well 143 for flow cytometry. EphA4 expression was not detected in EphA4 single knockout cells and in the 144 EphA2/EphA4 double knockout cells ( Fig. 3B ). We next examined the effect of EphA2 and EphA4 145 knockout on KSHV fusion. We found that knockout of EphA2 and EphA4 individually 146 dramatically decreased fusion activity (Fig. 3C ). In the EphA2 and EphA4 double knockout cells, 147 fusion activity was further decreased compared to single knockout cells ( Fig. 3C ). When EphA2 or 148
EphA4 were overexpressed in the double knockout cells, fusion activity was rescued ( Fig. 3D) . being the better receptor in the assays used in our current studies. 9 gH/gL at 4 C. The binding of EphA2 or EphA4 with EBV or KSHV gH/gL was then determined by 166 CELISA or western blotting ( Fig. 4A and 4B ). The CELISA data showed that EphA2 can bind to 167 both EBV and KSHV gH/gL, but with higher levels for KSHV gH/gL ( Fig. 4A ). However, EphA4 168 only bound to KSHV gH/gL and not EBV gH/gL (Fig. 4A ). This is consistent with the observation 169 that EphA4 expression does not increase EBV fusion. When soluble EphA2-Fc is co-expressed 170 with EBV gH/gL, KSHV gH/gL, or control vector transfected cells, soluble EphA2-Fc can bind to 171 both EBV and KSHV gH/gL as detected by CELISA ( Fig. 4C ). However, soluble EphA4-Fc can 172 only be detected when KSHV gH/gL are co-expressed and not with EBV gH/gL ( Fig. 4D ). These 173 data confirmed that KSHV gH/gL can bind to both EphA2 and EphA4, whereas EBV gH/gL binds 174 better to EpHA2 when compared to EphA4 (Fig. 4A ). There was some difference in the efficiency 175 of EphA2 binding to KSHV gH/gL and EBV gH/gL when Fig. 4A and 4C are compared. This is 176 likely a result of the different methods used to detect binding as described in the legend for Fig. 4 well in KSHV fusion ( Fig. 5A and 5B ). Interestingly, the EphA4A2 chimera functioned better in 189 fusion than the EphA2A4 chimera indicating that the LBD domain may be responsible for the greater 190 fusion activity observed for EphA4 when compared to EphA2. 191 Previous studies had demonstrated that the kinase region of EphA2 was important for KSHV 192 endocytosis (10) and subsequent entry. Our previous results demonstrated the EphA2 kinase 193 function was not important for EBV mediated cell-cell fusion (12). To investigate if the kinase 194 function was also nonessential for KSHV cell-cell fusion, we constructed three EphA4 kinase-dead 195 mutants based on previous studies (27, 28) similar to the EphA2 constructs that we used in our 196 previous study with EBV (12). In these constructs, tyrosine 596, 602, and 779 were all mutated 197 individually to alanine. These three mutants all lack kinase activity based on prior mutagenesis 198 studies (29, 30). The three EphA4 kinase dead mutants were transfected into HEK293T cells. 199
Fusion activity of the mutants compared to WT EphA4 ( and EphA4 double knock out cells (Fig. 3) . These findings indicate that EphA4 might be a novel 215 factor important for KSHV infection and may play a role in KS pathogenesis. 216
Recently, EphA2 has been identified as the receptor for several viruses and as an epithelial cell 217 pattern recognition receptor for fungal B-glucans (31). The human blood-brain barrier internalizes 218
Cryptococcus neoformans via EphA2 (32). EphA2 is a receptor for KSHV and EBV and a cellular 219 co-factor for hepatitis C virus entry (33). Additionally, ephrinB2, one ligand of this family, has been 220 identified as a receptor for Nipah virus (34, 35). Thus, the Eph family and its ligands are entry factors 221 for many pathogens. 222
Cell entry by KSHV is a multistep process involving viral envelope glycoproteins as well as 223 cellular receptors and other cofactors leading to the merger of virus and host membranes (5). The 224 binding receptors for KSHV include surface heparan sulfate (HS), which promotes a charge-based 225 interaction between virus glycoproteins and the cell surface. Integrins such as α3β1, αVβ3, and 226 αVβ5 play a crucial role in KSHV infection (6). xCT, a 12-transmembrane glutamate/cystine 227 exchange transporter protein, and DC-SIGN have also been reported to be entry receptors for KSHV 228 (7-9). More recently, EphA2 was identified as receptor that mediates KSHV infection of epithelial 229 and endothelial cells (10). After the identification of EphA2 as the receptor for KSHV, Hahn The function of gH/gL is to provide a key function in herpesvirus fusion to trigger gB activation and 234 subsequent membrane fusion. Our previous results found that compared to EBV gB, KSHV gB is a 235 poor fusogen (26). In our current study, we used this enhanced fusion function of EBV gB with 236 KSHV gH/gL to increase fusion activity to facilitate our current studies. We found that while only 237
EphA2 can enhance the fusion activity of EBV gH/gL, both EphA2 and EphA4 can enhance the 238 fusion activity of KSHV gH/gL ( Fig. 1A) , indicating the specificity of EphA4 for KSHV gH/gL. 239
Using a split GFP assay, we found that overexpression of EphA2 or EphA4 can induce fusion 240 compared to control cells, indicating that EphA2 or EphA4 alone is sufficient to serve as the receptor 241 for KSHV gH/gL ( Fig. 1B) . In WT HEK293T cells, overexpression of either EphA2 or EphA4 or 242 both can also enhance KSHV infection (Fig. 1C, 1D ). 243
EphA4 is widely expressed in different tissues and cell types (3). Using RNA-seq analysis we 244 found that EphA4 is expressed in B cells, fibroblasts, epithelial cells, and endothelial cells ( an integrin-independent route of KSHV infection and also suggests that multiple Eph receptors 253 besides EphA2 can promote and regulate infection, consistent with our findings (11) . 254
As a KSHV receptor, EphA2 binds to KSHV gH/gL at nM level (12, 37). Previous co-IP data 255 also showed that KSHV gH/gL can bind to EphA2, EphA4, EphA5 and EphB8 (28). We confirmed 256 that EphA4 can bind to KSHV gH/gL. Using three different methods, we showed that EphA2 can 257 13 bind to both EBV gH/gL and KSHV gH/gL independent of gB ( Fig. 4) contrast the last two amino acids in the ELEFN, F and N are structurally and biochemically quite 265 different than the G and H found in EBV gH suggesting that these two regions may be critical for 266 KSHV to use EphA2 and EphA4 as receptors. 267
Our results showed that EphA4 promotes KSHV fusion approximately 33% better than EphA2 268 ( Fig. 1A and Fig. 5B ) for KSHV fusion. Both KSHV gH/gL and EBV gH/gL binds to the EphA2 269 LBD domain, and the interaction can be competed with Ephrins (12, 13, 37 ). In the current study we 270 tested EphA2 and EphA4 LBD chimeras and found that the LBD of EphA2 and EphA4 is 271 interchangeable for KSHV fusion. Interestingly, it is the LBD that determines fusion activity since 272 the chimera containing the EphA4 LBD (EphA4A2) behaves more like wt EphA4 and this is also true 273 for EphA2A4 chimera (Fig. 5B ) 274
Previously, we examined if the kinase activity of EphA2 is important for the fusion of EBV 275 gH/gL and did not observe any loss of fusion function for the kinase-dead EphA2 mutants (12). In the 276 current study, we examined the kinase activity of EphA4 in the context of KSHV gH/gL fusion. 277
Similarly, we did not observe any changes between WT EphA4 and the EphA4 kinase-dead mutants 278 for fusion function. Previous work indicated that binding of KSHV gH/gL to EphA2 triggered 14 EphA4 kinase dead mutants, it is likely that the kinase function is important for infection by 281 functioning in endocytosis following virus binding (10). RNA-seq data assay-The RNA-seq data assay was performed as described in our previous paper 319 (12). Briefly, the Sequence Read Archive (SRA) data of RNA-seq for B cells (SRR5048157 and 320 SRR5048162), monocytes (SRR5048180 and SRR5048177), fibroblasts (SRR3192540 and 321 SRR3192539), epithelial cells (SRR3192374 and SRR3192375), and endothelial cells (SRR3192370 322 and SRR3192369) were downloaded from the SRA database (https://www.ncbi.nlm.nih.gov/sra). 323
The SRA data were transformed into the original FASTQ documents using NCBI SRA Toolkit 324 fastq-dump. The original documents were further trimmed using FASTX and aligned to the reference 325 genome using TopHat2. The differential expression analysis was performed using Cuffdiff software. 326
Generation of EphA2 and EphA4 single and double KO cells. For EphA2 and EphA4 single and 327
double KO cells, Cas9-expressing stable HEK293-T14 cells were established by infecting with 328 lentivirus containing Cas9 for 24 hours. 24 hours later, the cells were changed to fresh medium with 329 5 ug/mL blasticidin for selection. After one week, single colonies were picked as previously 330 described and expanded for 2-3 weeks (12). The Cas9 expression in these single cell colonies was 331 analyzed using Western blotting using the Flag tag fused to Cas9. 2.5 x 10 5 HEK293-T14-Cas9 cells 332 per well in a 12-well plate were infected with lentivirus including control sgRNA, EphA2 sgRNA, or 333 EphA4 sgRNA, either individually or combined together. The cells were selected with 2 ug/mL 334 puromycin and coloned as single cells as previously described (12). After 2-3 weeks of expansion, 335 knockout of EphA2 was confirmed by flow cytometry and the knockout of EphA4 was confirmed by 336
Western blotting. 337 Fusion assay. The virus-free cell-based fusion assay was performed as described previously 338 described (42) . Briefly, CHO-K1 cells grown to approximately 80% confluency in a 6-well plate and 339 were transiently transfected with T7 luciferase reporter plasmid with a T7 promoter (1.5 µg) and the 340 essential glycoproteins for EBV fusion gB (0.8 µg), EBV gH (0.5 µg), EBV gL (0. 
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